Comparative efficacy and safety of pharmacokinetically guided and body surface area–based 5-fluorouracil dosing in colorectal cancer: a systematic review and meta-analysis
- 3 September 2026
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (9) , 242
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use ApplicationClinical Pharmacokinetics, 2026
- Quantification of gimeracil, tegafur, and 5-FU in human plasma via LC-MS/MS with a simplified pretreatment using flow-through extractionJournal of Chromatography B, 2024
- First electrochemical bioplatform to assist in personalized 5-fluorouracil chemotherapySensors and Actuators B: Chemical, 2023
- Sex and gender perspectives in colorectal cancerESMO Open, 2023
- Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy—results of a prospective, multicenter German observational studyESMO Open, 2023
- Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil TherapyClinical Pharmacology & Therapeutics, 2018
- DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicityClinical Biochemistry, 2018
- P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targetingScientific Reports, 2017
- Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approachSeminars in Oncology, 2017
- Therapeutic drug monitoring of 5-fluorouracilCancer Chemotherapy and Pharmacology, 2016